Compare RMT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | GERN |
|---|---|---|
| Founded | 1993 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.0M | 821.1M |
| IPO Year | N/A | N/A |
| Metric | RMT | GERN |
|---|---|---|
| Price | $13.51 | $1.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 101.3K | ★ 14.2M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $8.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $1.04 |
| 52 Week High | $13.97 | $2.01 |
| Indicator | RMT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 32.94 |
| Support Level | $10.32 | $1.24 |
| Resistance Level | $13.97 | $1.29 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 54.13 | 10.42 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.